While hospitals continue to face IV saline shortages after two hurricanes significantly damaged infrastructure in Puerto Rico, the situation should improve early this year.
New blockbuster drugs to treat various conditions are expected to be among the top drugs to hit the marketplace in 2018. Here are 5 of the top new drugs in the pipeline for 2018, according to analysts.
FDA expanded the indication on cabozantinib (Cabometyx, Exelixis) to treat patients with advanced renal cell carcinoma (RCC).
FDA okays the first short-acting insulin approved as a “follow-on” product.
A new biosimilar to the cancer drug Herceptin, which raked in $2.5 billion in US sales last year, is expected to produce blockbuster sales in the US.
FDA approved a new cancer biomarker test that can detect genetic mutations in 324 genes and 2 genomic signatures in tumors.
FDA warned 4 companies, which are claiming that their products containing cannabidiol, can treat or cure cancer.
Pharma maker pleads guilty that one of its major drugs was misbranded in a federal court case brought by FDA and the US Department of Justice.
FDA is advising that these 2 opioid addiction medications should not be withheld from patients taking benzodiazepines or other drugs that depress the central nervous system.
FDA approved the first generic version of oseltamivir phosphate (Tamiflu, Roche) for oral suspension to treat influenza A and B, plus 2 other noteworthy therapies.
FDA warns about opioid-containing supplement

FDA said the manufacturer of dietary supplements containing kratom, a natural opioid used to treat opioid use disorder, ...

New warning on antibiotic for heart disease patients
Opioid prescription limits gain support
DEA tightens fentanyl scheduling

Event Resources


Stay current on the latest developments in your specialty with ModernMedicine's regularly updated collection of conference briefs and webinars.